Welcome to our dedicated page for Bolt Projects Holdings SEC filings (Ticker: BSLK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
This page compiles U.S. SEC filings for Bolt Projects Holdings, Inc. (Nasdaq: BSLK), a biomaterials company focused on the beauty and personal care industry. Through these documents, investors can review how the company reports on its Vegan Silk™ Technology Platform, capital structure, governance, and Nasdaq listing status.
Bolt Projects’ filings include Current Reports on Form 8-K, which disclose material events such as preliminary financial results, quarterly business updates, amendments to bylaws, equity financing arrangements, and notices related to Nasdaq listing compliance. For example, 8-K filings reference preliminary revenue and gross margin expectations, financing term sheets and equity line of credit agreements, and Nasdaq determinations regarding market value and equity listing standards.
The company also files registration statements, such as a Form S-1, describing equity line of credit facilities and the potential resale of common stock by a selling stockholder. These documents outline the terms of financing arrangements, risk factors, and Bolt Projects’ status as an emerging growth company and smaller reporting company. Proxy materials, including a Definitive Proxy Statement on Schedule 14A, provide information on matters submitted to stockholders, such as approvals related to convertible notes and warrants and adjournment proposals for special meetings.
Over time, investors can use annual reports on Form 10-K and quarterly reports on Form 10-Q (when available) to analyze segment information, revenue sources from the Vegan Silk platform, research and development spending, and liquidity and capital resources. Insider transaction reports on Form 4, when filed, offer visibility into equity transactions by directors and officers.
On Stock Titan, Bolt Projects’ SEC filings are updated as they are posted to EDGAR and are accompanied by AI-powered summaries that highlight key points, such as changes in guidance, new financing commitments, or updates to governance documents. These tools help readers quickly understand lengthy filings, compare successive reports, and identify disclosures related to listing compliance, equity facilities, and the company’s biomaterials-focused business model.
Bolt Projects Holdings, Inc. (BSLK) amended its bylaws effective October 17, 2025. The changes lower the stockholder meeting quorum to
The amendments add detailed disclosure and eligibility mechanics for stockholder nominations and other business, including background information requirements and a representation that nominees intend to serve their full term. They also cap nominations so stockholders cannot nominate more candidates than seats up for election.
Additional updates require any stockholder soliciting proxies to use a proxy card color other than white (reserved for the Board), clarify who may preside at meetings and that person’s authority, and update how Board vacancies may be filled. The full text appears as Exhibit 3.1.
Bolt Projects Holdings, Inc. received an updated Schedule 13G/A showing that Alta Partners LLC beneficially owns 48,819 ordinary shares, representing
Bolt Projects Holdings, Inc. (BSLK) received a Schedule 13G from Ascent Partners Fund LLC and affiliated reporting persons, disclosing beneficial ownership of 130,773 shares of common stock, or 5.4% of the class. As of October 7, 2025, Ascent directly holds 130,773 shares issued in connection with an equity purchase agreement dated September 12, 2025.
The filing lists no sole voting or dispositive power and shared voting and dispositive power over 130,773 shares among the reporting persons. The percentage is calculated based on 3,706,197 shares outstanding as of September 22, 2025, as disclosed by the issuer. The certification states the securities were not acquired to change or influence control.
Bolt Projects Holdings, Inc. reports that the Nasdaq Hearings Panel has granted it an extension to regain compliance with Nasdaq’s listing standards based on a plan the company presented. Instead of meeting market value tests, the company must now satisfy the minimum equity standard under Nasdaq Listing Rule 5550(b)(1) and will phase down to the Nasdaq Capital Market. The company’s plan targets achieving compliance by December 31, 2025, within the Panel’s permitted 180-day extension window. Bolt Projects is taking steps to meet the equity requirement and may seek a further extension, but there is no assurance it will regain or maintain compliance, and failure to do so could result in its securities being delisted from Nasdaq.
Bolt Projects Holdings, Inc. (BSLK) filed an S-1 describing a business centered on its Vegan Silk Technology Platform and material financial and operational risks. The filing discloses an accumulated deficit of $472.3 million, cash and equivalents of $1.0 million and negative net working capital of $5.5 million as of June 30, 2025, and cash used in operations of $2.9 million for the six months then ended, raising substantial doubt about the company's ability to continue as a going concern. Revenue is primarily from sales of the Vegan Silk Technology Platform, with concentrated customer and distributor relationships and reliance on a single manufacturing partner. The company identified material weaknesses in internal control over financial reporting and described steps taken, including hiring finance personnel and engaging consultants. The S-1 also describes potential Nasdaq delisting unless an appeal succeeds, various warrant and financing arrangements (including a Purchase Agreement that could yield up to $20.0 million of proceeds to the company), a 1-for-20 reverse stock split, and extensive risk factors related to manufacturing scale, competition, intellectual property, and regulatory and macro risks.
Bolt Projects Holdings, Inc. disclosed a Purchase Agreement with an investor that grants the company the ability to terminate the Purchase Agreement after commencement with five trading days' prior written notice, while the investor may terminate for a material uncured breach with ten trading days' notice (and a 15 trading day cure period if the breach is curable). The Purchase Agreement includes customary representations, warranties and indemnities and is filed as Exhibit 10.1. The company also entered a Registration Rights Agreement requiring it to register for resale under Rule 415 the shares sold under the facility and the Upfront Commitment Shares, filed as Exhibit 10.2. The company states the initial issuance will rely on Section 4(a)(2) of the Securities Act and estimates a maximum of 20,000,000 shares potentially issuable under the Purchase Agreement, with the actual number depending on use of the equity line of credit.